as of 11-16-2026 3:45pm EST
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | CHAPEL HILL |
| Market Cap: | 73.8M | IPO Year: | 2001 |
| Target Price: | $10.29 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | -16.52 |
| 52 Week Low/High: | $1.31 - $19.40 | Next Earning Date: | 11-05-2026 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.46 | Index: | |
| Free Cash Flow: | -35802323.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
10% Owner
Avg Cost/Share
$1.66
Shares
331,979
Total Value
$550,686.77
Owned After
7,447,000
SEC Form 4
10% Owner
Avg Cost/Share
$1.60
Shares
254,342
Total Value
$405,726.36
Owned After
7,447,000
SEC Form 4
10% Owner
Avg Cost/Share
$1.51
Shares
336,528
Total Value
$507,013.08
Owned After
7,447,000
SEC Form 4
Director
Avg Cost/Share
$1.92
Shares
53,000
Total Value
$101,760.00
Owned After
55,274
SEC Form 4
Avg Cost/Share
$1.82
Shares
4,850
Total Value
$8,837.19
Owned After
22,174
SEC Form 4
Avg Cost/Share
$1.88
Shares
6,000
Total Value
$11,250.00
Owned After
22,174
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$1.94
Shares
5,675
Total Value
$10,981.13
Owned After
15,675
SEC Form 4
10% Owner
Avg Cost/Share
$1.78
Shares
900,000
Total Value
$1,604,160.00
Owned After
7,447,000
SEC Form 4
10% Owner
Avg Cost/Share
$1.80
Shares
187,704
Total Value
$337,585.64
Owned After
7,447,000
SEC Form 4
10% Owner
Avg Cost/Share
$1.80
Shares
179,058
Total Value
$321,570.26
Owned After
7,447,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | TENX | 10% Owner | Oct 21, 2026 | Buy | $1.66 | 331,979 | $550,686.77 | 7,447,000 | |
| ADAR1 Capital Management, LLC | TENX | 10% Owner | Oct 20, 2026 | Buy | $1.60 | 254,342 | $405,726.36 | 7,447,000 | |
| ADAR1 Capital Management, LLC | TENX | 10% Owner | Oct 19, 2026 | Buy | $1.51 | 336,528 | $507,013.08 | 7,447,000 | |
| Doogan Declan | TENX | Director | Sep 16, 2026 | Buy | $1.92 | 53,000 | $101,760.00 | 55,274 | |
| Giordano Christopher Thomas | TENX | CEO | Sep 15, 2026 | Buy | $1.82 | 4,850 | $8,837.19 | 22,174 | |
| Giordano Christopher Thomas | TENX | CEO | Sep 11, 2026 | Buy | $1.88 | 6,000 | $11,250.00 | 22,174 | |
| STAAB THOMAS R II | TENX | Chief Financial Officer | Sep 11, 2026 | Buy | $1.94 | 5,675 | $10,981.13 | 15,675 | |
| ADAR1 Capital Management, LLC | TENX | 10% Owner | Sep 3, 2026 | Buy | $1.78 | 900,000 | $1,604,160.00 | 7,447,000 | |
| ADAR1 Capital Management, LLC | TENX | 10% Owner | Sep 2, 2026 | Buy | $1.80 | 187,704 | $337,585.64 | 7,447,000 | |
| ADAR1 Capital Management, LLC | TENX | 10% Owner | Sep 1, 2026 | Buy | $1.80 | 179,058 | $321,570.26 | 7,447,000 |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
-0.28%
$1.78
Act: +3.37%
5D
-3.42%
$1.72
20D
-30.14%
$1.25
2 d33477dex991.htm
Exhibit 99.1
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol
Company Has Been Granted a Type C Meeting with the FDA
CHAPEL HILL, N.C., November 5, 2026 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress.
On August 10, 2026, Tenax announced that LEVEL, the first Phase 3 clinical trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), did not achieve its primary or key secondary objectives, but did demonstrate evidence of beneficial biological effects on predefined cardiac biomarker and pulmonary hemodynamic measures in the overall population. Clinically meaningful improvements were observed in cardiac wall stress as measured by NT-proBNP (49% reduction, nominal p<0.0001) and in right ventricular systolic pressure (RVSP), an echocardiographic measure of pulmonary arterial pressure (reduction of 3.5 mmHg, nominal p=0.0045). Subgroup analyses identified a meaningful beneficial treatment effect in patients with the most advanced disease, defined by their limitation in exercise capacity, hemodynamic elevation in central venous pressure (CVP), pulmonary arterial pressure (PAP), and pulmonary capillary wedge pressure (PCWP), and elevated NT-proBNP levels. The treatment effect in the half of the LEVEL population with greater exercise impairment was manifested not only by clinically meaningful changes in 6-minute walk distance (6MWD), but also by greater improvement in pulmonary hemodynamic measures than was observed overall.
According to Stuart Rich, Chief Medical Officer of Tenax Therapeutics, “NT-proBNP and measures of PAP such as RVSP are independent biomarkers used in everyday diagnosis and treatment of patients with all forms of heart failure and pulmonary hypertension. Decades of research link improvements in both markers to reductions in mortality in patients suffering from these diseases. We believe the combination of robust reductions in both NT-proBNP and PAP in the patients treated with levosimendan support the hypothesis that levosimendan will provide meaningful chronic clinical effectiveness.”
On August 29, 2026, in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress, Professor Sanjiv Shah of Northwestern University Feinberg School of Medicine, who serves as LEVEL’s Principal Investigator, reviewed in more detail a prespecified analysis of the LEVEL population: in patients who walked less than the trial median of 333 meters at baseline, the levosimendan group demonstrated a 26.3 meter improvement in 6MWD as compared to the placebo group, a strong drug-treatment benefit in a more characteristic PH-HFpEF population. In this group of more symptomatic patients who demonstrated impressive exercise improvement, the observed RVSP reduction was greater than in the overall trial population (4.9 mmHg reduction, nominal p=0.009).
On October 8, 2026, the Company disclosed the completion of a multivariable analysis of LEVEL results that identified baseline characteristics as predictors of enhanced treatment response, described a predictive enrichment strategy for LEVEL-2 resulting from this analysis, and announced a temporary pause on LEVEL-2 enrollment while a protocol amendment is implemented at each site to ensure the population recruited for the trial meets these requirements. The enrichment criteria for LEVEL-2 were derived from a post hoc predictive enrichment analysis of the LEVEL data using a statistical methodology that estimates individual-level treatment effects using arm-specific regression models and then applies classification trees to identify baseline characteristics that distinguish treatment-responsive from non-responsive patients.
“Analysis of the results of the LEVEL trial provides insights into those patients who exhibit a significant improvement in exercise tolerance. With treatment continuing for those randomized prior to October, we believe we have now taken the steps necessary to ensure our LEVEL-2 protocol population will be enriched with these more symptomatic patients,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “In a LEVEL population with greater exercise limitation at baseline (i.e., lower 6MWD) and more pronounced echocardiographic evidence of volume overload causing their left heart disease, an improvement of 34 meters in 6MWD was observed after 12 weeks in this clinical trial. Our objective in LEVEL-2 is to enroll a population that conforms to this LEVEL subpopulation demonstrating significant treatment benefit on levos
Jul 31, 2026 · 100% conf.
1D
-1.90%
$13.44
Act: +4.60%
5D
-3.92%
$13.16
20D
-12.03%
$12.05
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1785586543.2f101061
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 12, 2026 · 100% conf.
1D
-1.74%
$11.96
Act: -2.22%
5D
-3.03%
$11.80
Act: -5.71%
20D
-11.39%
$10.78
Act: -13.31%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ce06d217.1784725246.e79fe6b9
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how TENX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TENX Tenax Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.